New combo therapy aims to turn inoperable liver cancer into operable
NCT ID NCT07368023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 300 people with liver cancer that could not be removed by surgery. About 100 received a combination of local treatments (like TACE or radiation) plus targeted drugs and immunotherapy, aiming to shrink tumors enough for surgery. The other 200 had surgery right away. Researchers will check how many tumors became removable and how long patients lived.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ningbo Medical Centre Lihuili Hospital
Ningbo, Zhejiang, 315000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new imaging agent could tell doctors which liver cancers will resist immunotherapy
- A new test could reveal how radiation affects the liver